D
Delonix Bioworks
A synthetic biology startup that engineers living medicines for infectious diseases and cancer
About Delonix Bioworks
Delonix Bio is a pioneering biotech startup that focuses on revolutionizing the development and manufacturing of medicines. The company operates at the intersection of synthetic biology, vaccinology, and cancer immunotherapies. Delonix Bio's core mission is to simplify and innovate the process of creating medicines by leveraging the natural capabilities of engineered microbes.
The company serves a diverse clientele, including pharmaceutical companies, healthcare providers, and research institutions. Delonix Bio operates in the highly specialized and competitive biotechnology market, which is dedicated to addressing some of the most challenging health issues, such as bacterial infections and cancer.
Delonix Bio's business model revolves around the design and engineering of bacteria to perform specific functions. This includes transforming pathogens into live vaccine vectors and converting biosubstances into protective agents. The company also focuses on synthetic cancer therapies, where engineered bacteria are used to destroy tumor cells and stimulate the immune system.
Revenue generation for Delonix Bio comes from multiple streams. Primarily, the company earns money through partnerships and collaborations with pharmaceutical companies and research institutions. These partnerships often involve co-development agreements, licensing deals, and milestone payments. Additionally, Delonix Bio may receive funding from grants and government contracts aimed at advancing innovative healthcare solutions.
In summary, Delonix Bio is at the forefront of biotech innovation, utilizing engineered microbes to create advanced medicines for complex health issues. The company’s unique approach and expertise position it as a leader in the biotechnology sector.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Huangpu, China
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 67.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Synthetic Biology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Mar 2021 | $14M | $56M | IDG Capital · ZhenFund · Boehringer Ingelheim Venture Fund | — |
| SPINOUT✓Other financing | Jan 2020 | $0 | — | The University of Hong Kong | — |
Growth signals
Latest recorded traffic for Delonix Bioworks is 1.1K monthly website visits, up 323.1% over the last three months. Delonix Bioworks's team grew 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Boehringer Ingelheim Venture Fund
IDG Capital
ZhenFund
Other known investors1 additional known investor
The University of Hong Kong
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Delonix Bioworks on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Delonix Bioworks’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.